$9.15
2.87% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US04635X1028
Symbol
ATXS
Sector
Industry

Astria Therapeutics Stock price

$9.15
-1.35 12.86% 1M
-0.07 0.76% 6M
+1.47 19.14% YTD
+1.29 16.41% 1Y
+3.67 66.97% 3Y
-26.01 73.98% 5Y
-770.85 98.83% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.27 2.87%
ISIN
US04635X1028
Symbol
ATXS
Sector
Industry

Key metrics

Market capitalization $516.37m
Enterprise Value $273.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.10
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-100.97m
Free Cash Flow (TTM) Free Cash Flow $-94.43m
Cash position $344.28m
EPS (TTM) EPS $-2.09
P/E forward negative
Short interest 4.94%
Show more

Is Astria Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Astria Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Astria Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Astria Therapeutics forecast:

Buy
100%

Financial data from Astria Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
40% 40%
-
- Research and Development Expense 69 69
71% 71%
-
-101 -101
60% 60%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -101 -101
60% 60%
-
Net Profit -100 -100
83% 83%
-

In millions USD.

Don't miss a Thing! We will send you all news about Astria Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Astria Therapeutics Stock News

Neutral
Business Wire
18 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein...
Neutral
Business Wire
19 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist, the company is developing as a potential tre...
Neutral
Business Wire
25 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria's common stock on December 2, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the gra...
More Astria Therapeutics News

Company Profile

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jill Milne
Employees 59
Founded 2008
Website www.astriatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today